Platelet function tests: a review of progresses in clinical application

Jae-Lim Choi, Shuhua Li, Jin-Yeong Han, Jae-Lim Choi, Shuhua Li, Jin-Yeong Han

Abstract

The major goal of traditional platelet function tests has been to screen and diagnose patients who present with bleeding problems. However, as the central role of platelets implicated in the etiology of arterial thrombotic diseases such as myocardial infarction and stroke became widely known, platelet function tests are now being promoted to monitor the efficacy of antiplatelet drugs and also to potentially identify patients at increased risk of thrombosis. Beyond hemostasis and thrombosis, an increasing number of studies indicate that platelets play an integral role in intercellular communication, are mediators of inflammation, and have immunomodulatory activity. As new potential biomarkers and technologies arrive at the horizon, platelet functions testing appears to take on a new aspect. This review article discusses currently available clinical application of platelet function tests, placing emphasis on essential characteristics.

References

    1. Smyth SS, Whiteheart S, Italiano JE, Jr., Coller BS. Williams Hematology. chapter 114. 2010. Platelet morphology, biochemistry, and function; pp. 1735–1814.
    1. Harrison P, Keeling D. Laboratory Hematology Practice. chapter 37. 2012. Platelet assays and platelet dysfunction; pp. 480–491.
    1. Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. International Journal of Laboratory Hematology. 2013;35(3):254–261.
    1. Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thrombosis and Haemostasis. 2009;102(2):248–257.
    1. Clemetson KJ. Platelets and primary haemostasis. Thrombosis Research. 2012;129(3):220–224.
    1. Abbate R, Cioni G, Ricci I, Miranda M, Gori AM. Thrombosis and Acute coronary syndrome. Thrombosis Research. 2012;129(3):235–240.
    1. Harrison P. Testing platelet function. Hematology/Oncology Clinics of North America. 2013;27(3):411–441.
    1. Pakala R, Waksman R. Currently available methods for platelet function analysis: advantages and disadvantages. Cardiovascular Revascularization Medicine. 2010;16(36):4041–4051.
    1. Hofer CK, Zollinger A, Ganter MT. Perioperative assessment of platelet function in patients under antiplatelet therapy. Expert Review of Medical Devices. 2010;7(5):625–637.
    1. Picker SM. In-vitro assessment of platelet function. Transfusion and Apheresis Science. 2011;44(3):305–319.
    1. Favaloro EJ, Lippi G, Franchini M. Contemporary platelet function testing. Clinical Chemistry and Laboratory Medicine. 2010;48(5):579–598.
    1. Kehrel BE, Brodde MF. State of the art in platelet function testing. Transfusion Medicine and Hemotherapy. 2013;40(2):73–86.
    1. Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2009;7(6):p. 1029.
    1. Dawood BB, Lowe GC, Lordkipanidze M, et al. Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel. Blood. 2012;120(25):5041–5049.
    1. Cattaneo M, Cerletti C, Harrison P, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party form the platelet physiology subcommittee of SSC/ISTH. Journal of Thrombosis and Haemostasis. 2013;11:1183–1189.
    1. Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function. Journal of Thrombosis and Haemostasis. 2006;4(2):312–319.
    1. Favaloro EJ. Clinical utility of the PFA-100. Seminars in Thrombosis and Hemostasis. 2008;34(8):709–733.
    1. Williams CD, Cherala G, Serebruany V. Application of platelet function testing to the bedside. Thrombosis and Haemostasis. 2010;103(1):29–33.
    1. Hezard N, Tessier-Marteau A, Macchi L. New insight in antiplatelet therapy monitoring in cardiovascular patients: from aspirin to thienopyridine. Cardiovascular and Hematological Disorders-Drug Targets. 2010;10(3):224–233.
    1. Dahlen JR, Price MJ, Parise H, Gurbel PA. Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. Thrombosis and Haemostasis. 2013;109(5):808–816.
    1. Afshari A, Wikkelsø A, Møller AM, Brok J, Wetterslev J. Thrombelastography (TEG) or thrombelastometry (ROTEM) to monitor haematotherapy versus usual care in patients with massive transfusion. Cochrane Database of Systematic Reviews. 2011;3:1–90.
    1. Kim B, Quan ML, Goh RY, et al. Comparison of prolonged prothrombin and activated partial thromboplastin time results with thrombeastograph parameters. Laboratory Medicine. 2013;44(4):319–323.
    1. Close SL. Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant? Fundamental and Clinical Pharmacology. 2012;26(1):19–26.
    1. Tobin WO, Kinsella JA, Coughlan T, et al. High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study. European Journal of Neurology. 2013;20(2):344–352.
    1. Capodanno D, Ferreiro JL, Angiolillo DJ. Antiplatelet therapy: new pharmacological agents and changing paradigms. Journal of Thrombosis and Haemostasis. 2013;11(supplement 1):316–329.
    1. Woo KS, Kim BR, Kim JE, et al. Detemination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests. Korean Journal of Laboratory Medicine. 2010;30(5):460–468.
    1. Kim KE, Woo KS, Goh RY, et al. Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients. International Journal of Laboratory Hematology. 2010;32(1):50–55.
    1. Smock KJ, Saunders PJ, Rodgers GM, Johari V. Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods. American Journal of Hematology. 2011;86(12):1032–1034.
    1. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. Journal of the American College of Cardiology. 2010;56(12):919–933.
    1. Aradi D, Storey RF, Komocsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal. 2014;35(4):209–215.
    1. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. Journal of the American College of Cardiology. 2013;62(24):2261–2273.
    1. Kunicki TJ, Nugent DJ. The genetics of normal platelet reactivity. Blood. 2010;116(15):2627–2634.
    1. Zhang HZ, Kim MH, Han JY, Jeong YH. Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI. Platelets. 2013
    1. Choi JL, Kim BR, Kim JE, et al. Association between the microarray-based CYP2C19 genotyping assay and the platelet function test in cardiovascular patients receiving clopidogrel. International Journal of Laboratory Hematology. 2014
    1. Prokopi M, Pula G, Mayr U, et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood. 2009;114(3):723–732.
    1. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circulation Research. 2010;107(9):1047–1057.
    1. Aatonen M, Grönholm M, Siljander P-M. Platelet-derived microvesicles: multitalented participants in intercellular communication. Seminars in Thrombosis and Hemostasis. 2012;38(1):102–113.
    1. Italiano JE, Jr., Mairuhu AT, Flaumenhaft R. Clinical relevance of microparticles from platelets and megakaryocytes. Current Opinion in Hematology. 2010;17(6):578–584.
    1. Shantsila E, Kamphuisen PW, Lip GYH. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. Journal of Thrombosis and Haemostasis. 2010;8(11):2358–2368.
    1. França CN, Pinheiro LFM, Izar MCO, et al. Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circulation Journal. 2012;76(3):729–736.
    1. Biasucci LM, Porto I, Vito LD, et al. Differences in microparticle release in patients with acute coronary syndrome and stable angina. Circulation Journal. 2012;76(9):2174–2182.
    1. Lackner P, Dietmann A, Beer R, et al. Cellular microparticles as a marker for cerebral vasospasm in spontaneous subarachnoid hemorrhage. Stroke. 2010;41(10):2353–2357.
    1. Thaler J, Ay C, Weinstabl H, et al. Circulating procoagulant microparticles in cancer patients. Annals of Hematology. 2011;90(4):447–453.
    1. Robert S, Poncelet P, Lacroix R, et al. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies? Journal of Thrombosis and Haemostasis. 2009;7(1):190–197.
    1. Mobarrez F, Antovic J, Egberg N, et al. A multicolor flow cytometric assay for measurement of platelet-derived microparticles. Thrombosis Research. 2010;125(3):e110–e116.
    1. Lacroix R, Robert S, Poncelet P, Kasthuri RS, Key NS, Dignat-George F. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. Journal of Thrombosis and Haemostasis. 2010;8(11):2571–2574.
    1. Dangwal S, Thum T. MicroRNAs in platelet biogenesis and function. Thrombosis and Haemostasis. 2012;108(4):599–604.
    1. Edelstein LC, McKenzie SE, Shaw C, Holinstat MA, Kunapuli SP, Bray PF. MicroRNAs in platelet production and activation. Journal of Thrombosis and Haemostasis. 2013;11(supplement 1):340–350.
    1. Willeit P, Zampetaki A, Dudek K, et al. Circulating microRNAs as novel biomarkers for platelet activation. Circulation Research. 2013;112(4):595–600.
    1. Zampetaki A, Willeit P, Tilling L, et al. Prospective study on circulating microRNAs and risk of myocardial infarction. Journal of the American College of Cardiology. 2012;60(4):290–299.
    1. Grasedieck S, Sorrentino A, Langer C, et al. Circulating microRNAs in hematological diseases: principles, challenges, and perspectives. Blood. 2013;121(25):4977–4984.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj